Does Aspruzyo Sprinkle 1,000 Mg Granules,Extended Release In Packet Antianginal And Anti-Ischemic Agents, Non-Hemodynamic Interact with other Medications?
Severe Interactions
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- RANOLAZINE/STRONG CYP3A4 INHIBITORS; PROTEASE INHIBITORS
- RANOLAZINE/STRONG CYP3A4 INDUCERS
- RANOLAZINE (> 500 MG BID)/MODERATE CYP3A4 INHIBITORS
- RANOLAZINE/STRONG CYP3A4 INHIBITORS THAT PROLONG QT
- P-GLYCOPROTEIN (P-GP) INHIB/COLCHICINE (CARDIOPROTECTION)
- WEAK CYP3A4 INHIBITORS/LEMBOREXANT (> 5 MG)
- WEAK CYP3A4 INHIBITORS/LOMITAPIDE (>30 MG)
- QT PROLONGING AGENTS/ANAGRELIDE
- RANOLAZINE/SIMVASTATIN (> 20 MG)
- QT PROLONGING AGENTS/ARTEMETHER-LUMEFANTRINE
Serious Interactions
These medications may interact and cause very harmful effects. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- RANOLAZINE (EXTENDED RELEASE GRANULES)/ALCOHOL
- P-GLYCOPROTEIN (P-GP) INHIBITORS/VINCRISTINE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/PRALSETINIB
- DISOPYRAMIDE; RANOLAZINE/MAVACAMTEN
- P-GLYCOPROTEIN (P-GP) INHIBITORS/BILASTINE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/DOXORUBICIN
- P-GP INHIBITORS/RIMEGEPANT
- P-GLYCOPROTEIN (P-GP) INHIBITORS/RELUGOLIX
- P-GP OR BCRP INHIBITORS THAT PROLONG QT/PAZOPANIB
- P-GP INHIBITORS THAT PROLONG QT/ORAL LEFAMULIN
- WEAK CYP3A4 INHIBITORS/ELIGLUSTAT
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/VENETOCLAX
- P-GLYCOPROTEIN (P-GP) INHIBITORS/COLCHICINE
- QT PROLONGING AGENTS/CITALOPRAM
- QT PROLONGING AGENTS/TRAZODONE (>= 100 MG)
- WEAK CYP3A4 INHIBITORS/LOMITAPIDE (<=30MG)
- QT PROLONGING AGENTS/PROPAFENONE
- QT PROLONGING AGENTS/TOREMIFENE
- P-GLYCOPROTEIN (P-GP) INHIBITORS/TOPOTECAN
- QT PROLONGING AGENTS/ZUCLOPENTHIXOL
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/DABIGATRAN
- POSSIBLE QT PROLONGING AGENTS/DISOPYRAMIDE
- SELECTED QT PROLONGING AGENTS/ZIPRASIDONE
- POSSIBLE QT PROLONGING AGENTS/SERTINDOLE
Moderate Interactions
These medications may cause some risk when taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- RANOLAZINE/QT PROLONGING AGENTS
- RANOLAZINE (<=500 MG BID)/MODERATE CYP3A4 INHIBITORS
- RANOLAZINE/SELECTED ANTIARRHYTHMICS
- POSSIBLE QT PROLONGING AGENTS/DEXMEDETOMIDINE SUBLINGUAL
- QT PROLONGING AGENTS/ETRASIMOD
- QT PROLONGING AGENTS/GEPIRONE
- POSSIBLE QT PROLONGING AGENTS/QUIZARTINIB
- QT PROLONGING AGENTS/TUCIDINOSTAT
- QT PROLONGING AGENTS/SAVOLITINIB
- QT PROLONGING AGENTS/TRICLABENDAZOLE
- POSSIBLE QT PROLONGING AGENTS/PACRITINIB
- QT PROLONGING AGENTS/TOLTERODINE
- SLT MODERATE AND WEAK CYP3A4 INHIBIT/SIROLIMUS PROTEIN-BOUND
- SELECTED POSSIBLE QT PROLONGING AGENTS/INTRAVENOUS LEFAMULIN
- POSSIBLE QT PROLONGING AGENTS/MOBOCERTINIB
- QT PROLONGING AGENTS/OZANIMOD
- QT PROLONGING AGENTS/PONESIMOD
- QT PROLONGING AGENTS/SIPONIMOD
- POSSIBLE QT PROLONGING AGENTS/FEXINIDAZOLE
- QT PROLONGING AGENTS/GALANTAMINE
- POSSIBLE QT PROLONGING AGENTS/LEVOMEPROMAZINE
- POSSIBLE QT PROLONGING AGENTS/SELPERCATINIB
- POSSIBLE QT PROLONGING AGENTS/OXALIPLATIN
- QT PROLONGING AGENTS/OSILODROSTAT
- QT PROLONGING AGENTS/AMISULPRIDE
- WEAK CYP3A4 INHIBITORS/UBROGEPANT
- WEAK CYP3A4 INHIBITORS/LEMBOREXANT (<= 5 MG)
- MODERATE & WEAK CYP3A4 INHIBITORS THAT PROLONG QT/TACROLIMUS
- POSSIBLE QT PROLONGING AGENTS/HYDROXYCHLOROQUINE
- QT PROLONGING AGENTS/PITOLISANT
- SODIUM CHANNEL BLOCKER; POTASSIUM CHANNEL BLOCKER/LACOSAMIDE
- QT PROLONGING AGENTS/GILTERITINIB
- POSSIBLE QT PROLONGING AGENTS/GLASDEGIB
- RANOLAZINE/ATORVASTATIN
- SELECT P-GP INHIBITORS/EDOXABAN (<= 30 MG)
- QT PROLONGING AGENTS/TRAZODONE (< 100 MG)
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/BETRIXABAN
- QT PROLONGING AGENTS/EFAVIRENZ
- POSSIBLE QT PROLONGING AGENTS/HYDROXYZINE
- POSSIBLE QT PROLONGING AGENTS/PIMAVANSERIN
- POSSIBLE QT PROLONGING AGENTS/OSIMERTINIB
- POSSIBLE QT PROLONGING AGENTS/SULPIRIDE
- SELECT P-GP INHIBITORS/EDOXABAN (> 30 MG)
- POSSIBLE QT PROLONGING AGENTS/LENVATINIB
- POSSIBLE QT PROLONGING AGENTS/DELAMANID
- RANOLAZINE/METFORMIN
- P-GLYCOPROTEIN (P-GP) INHIBITORS/AFATINIB
- QT PROLONGING AGENTS/FINGOLIMOD
- SELECTED P-GP AND WEAK CYP3A4 INHIBITORS/RIVAROXABAN
- SELECTED QT PROLONGERS/ASTEMIZOLE; TERFENADINE
- POSSIBLE QT PROLONGING AGENTS/GADOFOSVESET
- SELECTED CYP2D6 INHIBITORS/METOPROLOL
- POSSIBLE QT PROLONGING AGENTS/ROMIDEPSIN
- RANOLAZINE/DIGOXIN
- RANOLAZINE/SIMVASTATIN (<=20 MG); LOVASTATIN
- CYP3A4; CYP2C8; P-GLYCOPROTEIN (P-GP) INHIBITORS/LOPERAMIDE
- POSSIBLE QT PROLONGING AGENTS/AMIODARONE
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.